Rigel Pharmaceuticals, Inc. announced the upcoming presentation of four posters highlighting data from their commercial and clinical-stage hematology-oncology portfolio at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, California and virtually. The American Cancer Society estimates that in the United States alone, there will be about 20,380 new cases, most in adults, in 2023. Relapsed AML affects about half of all patients who, following treatment and remission, experience a return of leukemia cells in the bone marrow.

Refractory AML, which affects between 10 and 40% of newly diagnosed patients, occurs when a patient fails to achieve remission even after intensive treatment. Quality of life declines for patients with each successive line of treatment for AML, and well-tolerated treatments in relapsed or refractory disease remain an unmet need.